Oxford Biomedica PLC Director Dealings (4830A)

TIDMOXB

RNS Number : 4830A

Oxford Biomedica PLC

29 September 2020

Director Dealings

Oxford, UK - 29 September 2020: Oxford Biomedica plc ("Oxford Biomedica" or "the Group") (LSE: OXB), a leading gene and cell therapy group, today announces that Vulpes Life Sciences Fund ("Vulpes"), whose portfolio manager Martin Diggle is a Non-Executive Director on the Board of Oxford Biomedica, has entered into a pledge of security of 750,000 ordinary shares ("Transferred Shares") in connection with a financing transaction in the normal course of business for Vulpes.

Vulpes is required to redeem the Transferred Shares at maturity when the loan is repaid at the end of the three year term.

Following this transaction Vulpes Testudo/Vulpes Life Sciences Fund holds 10,713,616 ordinary shares representing 13.0% of the Company.

The below notification, made in accordance with the requirements of the EU Market Abuse Regulation, gives further detail of the transaction in number of Ordinary Shares.

 
 1.   Details of the person discharging material responsibilities/person 
       closely associated 
 a.   Name                                    Vulpes Life Sciences Fund 
 2.   Reason for the notification 
 a.   Position/status                             Martin Diggle, Non-Executive Director 
 b.   Initial notification                   Initial notification 
       /amendment 
3.    Details of the issuer, emission allowance, market 
       participant, auction platform, auctioneer or auction 
       monitor 
 a.   Name                                   Oxford Biomedica plc 
 b.   Legal Entity Identifier                213800S1GVQNXQ15K851 
4.    Details of the transaction(s); section to be repeated 
       for (i) each type of instrument; (ii) each type of 
       transaction; (iii) each date; and (iv) each place 
       where transactions have been conducted 
 a.   Description of                         Oxford Biomedica plc Ordinary Shares 
       the financial                          of 50p each 
       instrument, type                       GB00BDFBVT43 
       of instrument 
       identification 
       code 
b.    Nature of the                         Pledge of ordinary shares as a security 
       transaction                           in relation to a corporate loan 
c.    Currency                               GBP - British Pound 
d.    Price(s) and volume(s)                    Price(s)               Volume(s) 
        NA                                                               750,000 
 
e.          Aggregated information           750,000 
              *    Aggregated volume          NA 
                                              NA 
 
              *    Price 
 
 
              *    Aggregated total 
f.    Date of the transaction                2020-09-25 
g.    Place of the transaction               Outside of a trading venue 
 

The issued share capital of the Group is 82,223,225 ordinary 50p shares.

-Ends-

 
 For further information, please contact: 
  Oxford Biomedica plc:                      Tel: [phone] 
   Natalie Walter, Company Secretary 
 

About Oxford Biomedica

Oxford Biomedica (LSE:OXB) is a leading, fully integrated, gene and cell therapy group focused on developing life changing treatments for serious diseases. Oxford Biomedica and its subsidiaries (the "Group") have built a sector leading lentiviral vector delivery platform (LentiVector(R)), which the Group leverages to develop in vivo and ex vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology, CNS disorders, liver diseases and respiratory disease. The Group has also entered into a number of partnerships, including with Novartis, Bristol Myers Squibb, Sanofi, Axovant Gene Therapies, Orchard Therapeutics, Santen, Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium and Imperial Innovations, through which it has long-term economic interests in other potential gene and cell therapy products. Additionally the group has signed a Clinical and Commercial Supply Agreement with AstraZeneca for manufacture of the adeno based COVID-19 vaccine candidate, AZN1222. Oxford Biomedica is based across several locations in Oxfordshire, UK and employs more than 580 people. Further information is available at www.oxb.com .

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHPPURCBUPUGCB

(END) Dow Jones Newswires

September 29, 2020 10:51 ET (14:51 GMT)